<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37267379</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>6</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Use of latent class analysis and patient reported outcome measures to identify distinct long COVID phenotypes: A longitudinal cohort study.</ArticleTitle><Pagination><StartPage>e0286588</StartPage><MedlinePgn>e0286588</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0286588</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0286588</ELocationID><Abstract><AbstractText Label="OBJECTIVES">We sought to 1) identify long COVID phenotypes based on patient reported outcome measures (PROMs) and 2) determine whether the phenotypes were associated with quality of life (QoL) and/or lung function.</AbstractText><AbstractText Label="METHODS">This was a longitudinal cohort study of hospitalized and non-hospitalized patients from March 2020 to January 2022 that was conducted across 4 Post-COVID Recovery Clinics in British Columbia, Canada. Latent class analysis was used to identify long COVID phenotypes using baseline PROMs (fatigue, dyspnea, cough, anxiety, depression, and post-traumatic stress disorder). We then explored the association between the phenotypes and QoL (using the EuroQoL 5 dimensions visual analogue scale [EQ5D VAS]) and lung function (using the diffusing capacity of the lung for carbon monoxide [DLCO]).</AbstractText><AbstractText Label="RESULTS">There were 1,344 patients enrolled in the study (mean age 51 &#xb1;15 years; 780 [58%] were females; 769 (57%) were of a non-White race). Three distinct long COVID phenotypes were identified: Class 1) fatigue and dyspnea, Class 2) anxiety and depression, and Class 3) fatigue, dyspnea, anxiety, and depression. Class 3 had a significantly lower EQ5D VAS at 3 (50&#xb1;19) and 6 months (54 &#xb1; 22) compared to Classes 1 and 2 (p&lt;0.001). The EQ5D VAS significantly improved between 3 and 6 months for Class 1 (median difference of 6.0 [95% CI, 4.0 to 8.0]) and Class 3 (median difference of 5.0 [95% CI, 0 to 8.5]). There were no differences in DLCO between the classes.</AbstractText><AbstractText Label="CONCLUSIONS">There were 3 distinct long COVID phenotypes with different outcomes in QoL between 3 and 6 months after symptom onset. These phenotypes suggest that long COVID is a heterogeneous condition with distinct subpopulations who may have different outcomes and warrant tailored therapeutic approaches.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2023 Wong et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Alyson W</ForeName><Initials>AW</Initials><Identifier Source="ORCID">0000-0003-4910-1948</Identifier><AffiliationInfo><Affiliation>Department of Medicine, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Karen C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binka</LastName><ForeName>Mawuena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Data and Analytic Services, BC Centre for Disease Control, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Population and Public Health, The University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janjua</LastName><ForeName>Naveed Z</ForeName><Initials>NZ</Initials><AffiliationInfo><Affiliation>Data and Analytic Services, BC Centre for Disease Control, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Population and Public Health, The University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sbihi</LastName><ForeName>Hind</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Data and Analytic Services, BC Centre for Disease Control, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Population and Public Health, The University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russell</LastName><ForeName>James A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Centre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carlsten</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Population and Public Health, The University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>Adeera</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryerson</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HEC 181075</GrantID><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077272" MajorTopicYN="N">Latent Class Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004417" MajorTopicYN="N">Dyspnea</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071066" MajorTopicYN="N">Patient Reported Outcome Measures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001955" MajorTopicYN="N" Type="Geographic">British Columbia</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>19</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>14</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37267379</ArticleId><ArticleId IdType="pmc">PMC10237387</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0286588</ArticleId><ArticleId IdType="pii">PONE-D-23-03084</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nasserie T, Hittle M, Goodman SN. Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review. JAMA Netw Open. 2021;4(5):e2111417. doi: 10.1001/jamanetworkopen.2021.11417 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.11417</ArticleId><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Deans AR, Lewis SE, Huala E, Anzaldo SS, Ashburner M, Balhoff JP, et al.. Finding our way through phenotypes. PLoS Biol. 2015;13(1):e1002033. doi: 10.1371/journal.pbio.1002033 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1002033</ArticleId><ArticleId IdType="pmc">PMC4285398</ArticleId><ArticleId IdType="pubmed">25562316</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontera JA, Thorpe LE, Simon NM, de Havenon A, Yaghi S, Sabadia SB, et al.. Post-acute sequelae of COVID-19 symptom phenotypes and therapeutic strategies: A prospective, observational study. PLoS One. 2022;17(9):e0275274. doi: 10.1371/journal.pone.0275274 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0275274</ArticleId><ArticleId IdType="pmc">PMC9521913</ArticleId><ArticleId IdType="pubmed">36174032</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenny G, McCann K, O&#x2019;Brien C, Savinelli S, Tinago W, Yousif O, et al.. Identification of Distinct Long COVID Clinical Phenotypes Through Cluster Analysis of Self-Reported Symptoms. Open Forum Infect Dis. 2022;9(4):ofac060. doi: 10.1093/ofid/ofac060 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac060</ArticleId><ArticleId IdType="pmc">PMC8900926</ArticleId><ArticleId IdType="pubmed">35265728</ArticleId></ArticleIdList></Reference><Reference><Citation>Reese JT, Blau H, Casiraghi E, Bergquist T, Loomba JJ, Callahan TJ, et al.. Generalisable long COVID subtypes: findings from the NIH N3C and RECOVER programmes. EBioMedicine. 2023;87:104413. doi: 10.1016/j.ebiom.2022.104413 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104413</ArticleId><ArticleId IdType="pmc">PMC9769411</ArticleId><ArticleId IdType="pubmed">36563487</ArticleId></ArticleIdList></Reference><Reference><Citation>Canadian Institute for Health Information. Patient-reported outcome measures (PROMs) [August 24, 2020]. https://www.cihi.ca/en/patient-reported-outcome-measures-proms.</Citation></Reference><Reference><Citation>Wong AW, Shah AS, Johnston JC, Carlsten C, Ryerson CJ. Patient-reported outcome measures after COVID-19: a prospective cohort study. Eur Respir J. 2020;56(5). doi: 10.1183/13993003.03276-2020 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.03276-2020</ArticleId><ArticleId IdType="pmc">PMC7530908</ArticleId><ArticleId IdType="pubmed">33008936</ArticleId></ArticleIdList></Reference><Reference><Citation>EuroQol. EuroQoL instruments [February 10, 2021]. https://euroqol.org/eq-5d-instruments/.</Citation></Reference><Reference><Citation>Mendez R, Latorre A, Gonzalez-Jimenez P, Feced L, Bouzas L, Yepez K, et al.. Reduced Diffusion Capacity in COVID-19 Survivors. Ann Am Thorac Soc. 2021;18(7):1253&#x2013;5. doi: 10.1513/AnnalsATS.202011-1452RL .</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.202011-1452RL</ArticleId><ArticleId IdType="pmc">PMC8328367</ArticleId><ArticleId IdType="pubmed">33472019</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo X, Jian W, Su Z, Chen M, Peng H, Peng P, et al.. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur Respir J. 2020;55(6). doi: 10.1183/13993003.01217-2020 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01217-2020</ArticleId><ArticleId IdType="pmc">PMC7236826</ArticleId><ArticleId IdType="pubmed">32381497</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah AS, Ryu MH, Hague CJ, Murphy DT, Johnston JC, Ryerson CJ, et al.. Changes in pulmonary function and patient-reported outcomes during COVID-19 recovery: a longitudinal, prospective cohort study. ERJ Open Res. 2021;7(3). doi: 10.1183/23120541.00243-2021 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00243-2021</ArticleId><ArticleId IdType="pmc">PMC8310958</ArticleId><ArticleId IdType="pubmed">34522693</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah AS, Wong AW, Hague CJ, Murphy DT, Johnston JC, Ryerson CJ, et al.. A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations. Thorax. 2021;76(4):402&#x2013;4. doi: 10.1136/thoraxjnl-2020-216308 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-216308</ArticleId><ArticleId IdType="pubmed">33273023</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41(11):1284&#x2013;92. doi: 10.1097/01.MLR.0000093487.78664.3C .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.MLR.0000093487.78664.3C</ArticleId><ArticleId IdType="pubmed">14583691</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke K, Spitzer RL, Williams JB, Monahan PO, Lowe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007;146(5):317&#x2013;25. doi: 10.7326/0003-4819-146-5-200703060-00004 .</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-146-5-200703060-00004</ArticleId><ArticleId IdType="pubmed">17339617</ArticleId></ArticleIdList></Reference><Reference><Citation>Kupferberg DH, Kaplan RM, Slymen DJ, Ries AL. Minimal clinically important difference for the UCSD Shortness of Breath Questionnaire. J Cardiopulm Rehabil. 2005;25(6):370&#x2013;7. doi: 10.1097/00008483-200511000-00011 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00008483-200511000-00011</ArticleId><ArticleId IdType="pubmed">16327533</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin Nguyen A, Bacci ED, Vernon M, Birring SS, Rosa C, Muccino D, et al.. Validation of a visual analog scale for assessing cough severity in patients with chronic cough. Ther Adv Respir Dis. 2021;15:17534666211049743. doi: 10.1177/17534666211049743 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17534666211049743</ArticleId><ArticleId IdType="pmc">PMC8552382</ArticleId><ArticleId IdType="pubmed">34697975</ArticleId></ArticleIdList></Reference><Reference><Citation>Prins A, Bovin MJ, Smolenski DJ, Marx BP, Kimerling R, Jenkins-Guarnieri MA, et al.. The Primary Care PTSD Screen for DSM-5 (PC-PTSD-5): Development and Evaluation Within a Veteran Primary Care Sample. J Gen Intern Med. 2016;31(10):1206&#x2013;11. doi: 10.1007/s11606-016-3703-5 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-016-3703-5</ArticleId><ArticleId IdType="pmc">PMC5023594</ArticleId><ArticleId IdType="pubmed">27170304</ArticleId></ArticleIdList></Reference><Reference><Citation>Valko PO, Bassetti CL, Bloch KE, Held U, Baumann CR. Validation of the fatigue severity scale in a Swiss cohort. Sleep. 2008;31(11):1601&#x2013;7. doi: 10.1093/sleep/31.11.1601 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/sleep/31.11.1601</ArticleId><ArticleId IdType="pmc">PMC2579971</ArticleId><ArticleId IdType="pubmed">19014080</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha P, Calfee CS, Delucchi KL. Practitioner&#x2019;s Guide to Latent Class Analysis: Methodological Considerations and Common Pitfalls. Crit Care Med. 2021;49(1):e63&#x2013;e79. doi: 10.1097/CCM.0000000000004710 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000004710</ArticleId><ArticleId IdType="pmc">PMC7746621</ArticleId><ArticleId IdType="pubmed">33165028</ArticleId></ArticleIdList></Reference><Reference><Citation>Copay AG, Subach BR, Glassman SD, Polly DW Jr., Schuler TC. Understanding the minimum clinically important difference: a review of concepts and methods. Spine J. 2007;7(5):541&#x2013;6. doi: 10.1016/j.spinee.2007.01.008 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.spinee.2007.01.008</ArticleId><ArticleId IdType="pubmed">17448732</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70. doi: 10.1186/1477-7525-5-70 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-7525-5-70</ArticleId><ArticleId IdType="pmc">PMC2248572</ArticleId><ArticleId IdType="pubmed">18154669</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai APY, Hur SA, Wong A, Safavi M, Assayag D, Johannson KA, et al.. Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung disease. Thorax. 2021;76(1):37&#x2013;43. doi: 10.1136/thoraxjnl-2020-214944 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-214944</ArticleId><ArticleId IdType="pubmed">33023996</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanini A, Aiello M, Adamo D, Casale S, Cherubino F, Della Patrona S, et al.. Estimation of minimal clinically important difference in EQ-5D visual analog scale score after pulmonary rehabilitation in subjects with COPD. Respir Care. 2015;60(1):88&#x2013;95. doi: 10.4187/respcare.03272 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4187/respcare.03272</ArticleId><ArticleId IdType="pubmed">25336531</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssen B, Szende A. Population Norms for the EQ-5D. In: Szende A, Janssen B, Cabases J, editors. Self-Reported Population Health: An International Perspective based on EQ-5D. Dordrecht (NL) 2014. p. 19&#x2013;30.</Citation></Reference><Reference><Citation>Di Marco F, Verga M, Reggente M, Maria Casanova F, Santus P, Blasi F, et al.. Anxiety and depression in COPD patients: The roles of gender and disease severity. Respir Med. 2006;100(10):1767&#x2013;74. doi: 10.1016/j.rmed.2006.01.026 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2006.01.026</ArticleId><ArticleId IdType="pubmed">16531031</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner P, Magadle R, Massarwa F, Beckerman M, Berar-Yanay N. Influence of gender and inspiratory muscle training on the perception of dyspnea in patients with asthma. Chest. 2002;122(1):197&#x2013;201. doi: 10.1378/chest.122.1.197 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.122.1.197</ArticleId><ArticleId IdType="pubmed">12114358</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans RA, McAuley H, Harrison EM, Shikotra A, Singapuri A, Sereno M, et al.. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir Med. 2021;9(11):1275&#x2013;87. doi: 10.1016/S2213-2600(21)00383-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00383-0</ArticleId><ArticleId IdType="pmc">PMC8497028</ArticleId><ArticleId IdType="pubmed">34627560</ArticleId></ArticleIdList></Reference><Reference><Citation>Prevention CfDCa. COVID Data Tracker [February 2, 2023]. https://covid.cdc.gov/covid-data-tracker.</Citation></Reference><Reference><Citation>Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, Hastie C, et al.. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021;6(9). doi: 10.1136/bmjgh-2021-005427 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-005427</ArticleId><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>